Impact of a blood-stage vaccine on Plasmodium vivax malaria

BACKGROUND: There are no licensed vaccines against Plasmodium vivax, the most common cause of malaria outside of Africa. METHODS: We conducted two Phase I/IIa clinical trials to assess the safety, immunogenicity and efficacy of two vaccines targeting region II of P. vivax Duffy-binding protein (PvDB...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Mimi M., Barrett, Jordan R., Themistocleous, Yrene, Rawlinson, Thomas A., Diouf, Ababacar, Martinez, Francisco J., Nielsen, Carolyn M., Lias, Amelia M., King, Lloyd D. W., Edwards, Nick J., Greenwood, Nicola M., Kingham, Lucy, Poulton, Ian D., Khozoee, Baktash, Goh, Cyndi, Mac Lochlainn, Dylan J., Salkeld, Jo, Guilotte-Blisnick, Micheline, Huon, Christèle, Mohring, Franziska, Reimer, Jenny M., Chauhan, Virander S., Mukherjee, Paushali, Biswas, Sumi, Taylor, Iona J., Lawrie, Alison M., Cho, Jee-Sun, Nugent, Fay L., Long, Carole A., Moon, Robert W., Miura, Kazutoyo, Silk, Sarah E., Chitnis, Chetan E., Minassian, Angela M., Draper, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164524/
https://www.ncbi.nlm.nih.gov/pubmed/35664997
http://dx.doi.org/10.1101/2022.05.27.22275375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164524/
https://www.ncbi.nlm.nih.gov/pubmed/35664997
http://dx.doi.org/10.1101/2022.05.27.22275375

Ejemplares similares